MX2018010201A - Formulacion liquida estable de gonadotropina. - Google Patents

Formulacion liquida estable de gonadotropina.

Info

Publication number
MX2018010201A
MX2018010201A MX2018010201A MX2018010201A MX2018010201A MX 2018010201 A MX2018010201 A MX 2018010201A MX 2018010201 A MX2018010201 A MX 2018010201A MX 2018010201 A MX2018010201 A MX 2018010201A MX 2018010201 A MX2018010201 A MX 2018010201A
Authority
MX
Mexico
Prior art keywords
stable liquid
formulation
liquid gonadotropin
gonadotropin formulation
stabilization
Prior art date
Application number
MX2018010201A
Other languages
English (en)
Inventor
Ulrika Sjögren Helen
Højer-Pedersen Charlotte
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018010201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2018010201A publication Critical patent/MX2018010201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere en general al campo de la estabilización de formulaciones de gonadotropina, en particular formulaciones líquidas de gonadotropinas. La estabilización se logra mediante una combinación particular de excipientes, preferiblemente arginina y metionina. En una modalidad preferida, la formulación no comprende tampón alguno.
MX2018010201A 2016-02-24 2017-02-24 Formulacion liquida estable de gonadotropina. MX2018010201A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1603280.7A GB201603280D0 (en) 2016-02-24 2016-02-24 Stable liquid gonadotropin formulation
PCT/EP2017/054325 WO2017144659A1 (en) 2016-02-24 2017-02-24 Stable liquid gonadotropin formulation

Publications (1)

Publication Number Publication Date
MX2018010201A true MX2018010201A (es) 2019-06-06

Family

ID=55806922

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010201A MX2018010201A (es) 2016-02-24 2017-02-24 Formulacion liquida estable de gonadotropina.

Country Status (37)

Country Link
US (3) US10792334B2 (es)
EP (3) EP4257149A3 (es)
JP (3) JP6932710B2 (es)
KR (1) KR20180114178A (es)
CN (2) CN108883061B (es)
AR (1) AR107782A1 (es)
AU (2) AU2017222292B2 (es)
BR (1) BR112018015166A2 (es)
CA (1) CA3012759A1 (es)
CL (1) CL2018001984A1 (es)
CO (1) CO2018007810A2 (es)
DK (2) DK3791860T5 (es)
EA (1) EA036383B1 (es)
ES (2) ES2862193T3 (es)
FI (1) FI3791860T3 (es)
GB (1) GB201603280D0 (es)
HR (2) HRP20231477T1 (es)
HU (2) HUE064432T2 (es)
IL (1) IL260626B2 (es)
JO (1) JOP20170046B1 (es)
LT (2) LT3419595T (es)
MA (2) MA43686B1 (es)
MD (2) MD3791860T2 (es)
MX (1) MX2018010201A (es)
MY (1) MY193138A (es)
NZ (1) NZ744294A (es)
PH (1) PH12018501688A1 (es)
PL (2) PL3791860T3 (es)
PT (2) PT3791860T (es)
RS (2) RS64929B1 (es)
SG (1) SG11201806140SA (es)
SI (2) SI3419595T1 (es)
TN (1) TN2018000284A1 (es)
TW (1) TWI755377B (es)
UA (1) UA123107C2 (es)
WO (1) WO2017144659A1 (es)
ZA (1) ZA201804944B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
US20190262314A1 (en) * 2018-02-26 2019-08-29 Slayback Pharma Llc Ready-to-use dexmedetomidine compositions
US20220062177A1 (en) * 2018-10-02 2022-03-03 InnoCore Technologies Holding B.V. Extended release formulations of human chorionic gonadotropin (hcg)
CN112451652A (zh) * 2020-12-07 2021-03-09 苏州智核生物医药科技有限公司 一种重组人促甲状腺素注射液
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions
CN118209739A (zh) * 2024-03-19 2024-06-18 厦门宝太和瑞生物技术有限公司 促黄体生成素检测试剂盒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2198299C (en) 1996-02-28 2000-05-02 Yuhei Abe Card holder-type balance display
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
PL2219607T3 (pl) 2007-11-01 2012-12-31 Merck Serono Sa Ciekłe formulacje LH
CN101969971A (zh) 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
DE202009009905U1 (de) 2008-02-08 2009-10-29 Biogenerix Ag Flüssig-Formulierung von FSH
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
WO2011099036A2 (en) * 2010-02-12 2011-08-18 Intas Biopharmaceuticals Limited Liquid formulation of follicle stimulating hormone
WO2011108010A2 (en) 2010-03-05 2011-09-09 Intas Biopharmaceuticals Limited A thermostable liquid formulation of gonadotropins
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
IN2013MU03559A (es) * 2013-11-12 2015-07-24 Cadila Healthcare Ltd
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Also Published As

Publication number Publication date
EA036383B1 (ru) 2020-11-03
MA43686A (fr) 2019-01-02
CN108883061A (zh) 2018-11-23
LT3791860T (lt) 2023-12-11
ES2966262T3 (es) 2024-04-19
EP3791860A1 (en) 2021-03-17
EP3419595B1 (en) 2021-01-06
GB201603280D0 (en) 2016-04-13
JOP20170046B1 (ar) 2021-08-17
HRP20231477T1 (hr) 2024-03-01
MA43686B1 (fr) 2021-03-31
US20230372447A1 (en) 2023-11-23
UA123107C2 (uk) 2021-02-17
FI3791860T3 (fi) 2024-01-11
PL3419595T3 (pl) 2021-06-14
TN2018000284A1 (en) 2020-01-16
TWI755377B (zh) 2022-02-21
CN113398250A (zh) 2021-09-17
RS64929B1 (sr) 2023-12-29
RS61604B1 (sr) 2021-04-29
MY193138A (en) 2022-09-26
BR112018015166A2 (pt) 2018-12-18
JP2023164573A (ja) 2023-11-10
JP2019507153A (ja) 2019-03-14
AU2017222292B2 (en) 2021-12-16
EP4257149A3 (en) 2023-12-20
MA52595A (fr) 2021-03-17
TW201733612A (zh) 2017-10-01
IL260626B2 (en) 2023-08-01
NZ744294A (en) 2024-08-30
CL2018001984A1 (es) 2018-09-14
PT3419595T (pt) 2021-03-29
EP3791860B1 (en) 2023-10-11
JP6932710B2 (ja) 2021-09-08
ES2862193T3 (es) 2021-10-07
DK3419595T3 (da) 2021-03-29
CO2018007810A2 (es) 2018-10-22
US10792334B2 (en) 2020-10-06
SG11201806140SA (en) 2018-08-30
US20210236600A1 (en) 2021-08-05
EP3419595A1 (en) 2019-01-02
AU2022200027A1 (en) 2022-02-03
MA52595B1 (fr) 2023-12-29
LT3419595T (lt) 2021-03-10
PT3791860T (pt) 2023-12-15
MD3791860T2 (ro) 2024-03-31
DK3791860T3 (da) 2023-12-18
HRP20210367T1 (hr) 2021-04-16
ZA201804944B (en) 2023-02-22
CA3012759A1 (en) 2017-08-31
DK3791860T5 (da) 2024-08-19
IL260626A (es) 2018-09-20
IL260626B1 (en) 2023-04-01
HUE064432T2 (hu) 2024-03-28
EA201891905A1 (ru) 2019-02-28
PL3791860T3 (pl) 2024-03-18
MD3419595T2 (ro) 2021-06-30
JP2021191760A (ja) 2021-12-16
CN108883061B (zh) 2021-06-08
CN113398250B (zh) 2024-02-23
HUE053492T2 (hu) 2021-06-28
SI3791860T1 (sl) 2024-01-31
US11666635B2 (en) 2023-06-06
US20190060409A1 (en) 2019-02-28
EP4257149A2 (en) 2023-10-11
WO2017144659A1 (en) 2017-08-31
PH12018501688A1 (en) 2019-05-27
AU2017222292A1 (en) 2018-07-26
KR20180114178A (ko) 2018-10-17
SI3419595T1 (sl) 2021-04-30
AR107782A1 (es) 2018-06-06

Similar Documents

Publication Publication Date Title
PH12018501688A1 (en) Stable liquid gonadotropin formulation
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
MX2017017157A (es) Composiciones de bebida lista para beber estables que comprende agentes activos lipofilos.
MY187047A (en) Selective pyy compounds and uses thereof
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
EA201890343A1 (ru) Быстродействующие инсулиновые композиции
MX2021015789A (es) Reduccion de la viscosidad de formulaciones farmaceuticas.
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
EA201991798A1 (ru) Стабильные при хранении составы
AR098168A1 (es) Formulación estable de insulina glulisina
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
SG11201805123XA (en) Pharmaceutical composition comprising anti-human tslp receptor antibody
MX2019011545A (es) Composiciones celulares y de andamio inyectables.
PH12015502082A1 (en) Improved stability and potency of hemagglutinin
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
PH12018502089A1 (en) Pharmaceutical composition of dapagliflozin
GEP20237486B (en) Formulations of copanlisib
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.
GEP20196977B (en) Pharmaceutical formulations of vildagliptin
MX2017013879A (es) Composiciones que comprenden anakinra.
EA201791437A1 (ru) Композиции микросфер c инкапсулированным в липиде газом и соответствующие способы
CL2016000542A1 (es) Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis.
EA201690070A1 (ru) Применение аргинина и/или цитруллина для лечения и/или профилактики остеоартроза
UA106905U (uk) Фармацевтична композиція